Abstract: Provided herein compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichthyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

Abstract: Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder selected from psoriasis, dermatitis, acne, rosacea, ichthyosis, scaling skin, imbalance of skin barrier and tinea and exhibit synergistic and/or additive effects allowing to reduce the active agents amounts in the combination compositions.

Abstract: Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.

Abstract: Provided herein is a topical combination composition comprising tapinarof, an additional AhR activator and optionally further comprising at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions.

Abstract: Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent elected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.

Abstract: Disclosed are topical compositions and methods of treatment of a skin or mucosal disorder selected from palmoplantar psoriasis, hereditary palmoplantar keratoderma, acquired palmoplantar keratoderma, hydradenitis suppurativa, dermatitis, ichthyosis vulgaris, hereditary ichthyosis, acquired ichthyosis, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, Gorlin syndrome, nail psoriasis, flexural/inverse psoriasis, non-melanoma skin cancer, Cutaneous T-cell lymphoma and precancerous skin, mucosal and nail lesions, by once or twice daily topical administration to a subject of a composition comprising therapeutically effective amount of tapinarof.

Abstract: The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. Specifically, the ocular inflammatory disease is blepharitis. This invention provides a treatment of blepharitis and Demodex mites.

Abstract: The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGFR) inhibitor.

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

Abstract: The present invention, in some embodiments thereof, relates to a topical composition for use in treating, preventing, alleviating and/or ameliorating pruritus, wherein the composition comprises tapinarof and the pruritus is not associated with atopic dermatitis, psoriasis or any combination thereof.

Abstract: The present invention is directed to a composition comprising aryl hydrocarbon receptor (AhR) agonists and combinations for the prevention and treatment of alopecia and hair loss, e.g. when such conditions are caused by chemotherapy, radiation therapy or hormone replacement therapy.

Abstract: Provided herein is a topical combination composition comprising roflumilast, roflumilast N-oxide or pharmaceutically acceptable salt thereof, and at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO) and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above composition is useful for the treatment, prevention or alleviation of a skin disorder selected from acne and rosacea and exhibits synergistic and/or additive effects allowing to reduce the active agents amounts in the topical combination compositions.

Abstract: Provided herein is a topical composition comprising roflumilast, roflumilast N-oxide or salts thereof as an active agent. The active agent in the composition of this invention is in encapsulated or non-encapsulated form, according to need. The above composition is useful for the treatment, prevention or alleviation of a skin disorder selected from Hidradenitis suppurativa and Prurigo nodularis.

Abstract: The present invention, in some embodiments thereof, relates to topical compositions and methods of treatment, prevention and/or amelioration of granuloma annulare, a non-infection granulomatous disease, or a subcutaneous inflammation by topical or intralesional administration of compositions comprising tapinarof.

Abstract: The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, age-related macular degeneration and combinations thereof.

Abstract: The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), age-related macular degeneration and combinations thereof.

Abstract: The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention and/or alleviation of the symptoms of an ocular inflammatory disease or an ocular degeneration disease selected from uveitis, vitritis, dry eye disease (DED), macular degeneration, idiopathic orbital inflammatory disease (IOD), chorioretinal inflammation, keratitis, blepharitis, seborrheic dermatitis of eyelids, seborrheic dermatitis of eyebrows, hyperemia, thyroid eye disease (TED), age-related macular degeneration, orbital myositis, and combinations thereof.

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

Abstract: The invention provides a method of treating or preventing rosacea, comprising topical administration, of a pharmaceutical preparation comprising a nonsteroidal anti-inflammatory drug (NSAID).